ALX Oncology (ALXO)
Develops evorpacept and ALX2004 for clinical-stage cancer studies.
Something off on this page? Send us feedback.
Develops the CD47 blocker evorpacept and the EGFR-targeted ADC ALX2004. As a clinical-stage company, it has not realized product revenue from planned principal operations.
Clinical development centers on evorpacept, an engineered CD47 blocker, and ALX2004, an EGFR-targeted antibody-drug conjugate. Evorpacept is being studied in antibody combinations, including with trastuzumab and chemotherapy, while ALX2004 is in a dose-escalation and expansion program for EGFR-expressing solid tumors. Development is concentrated on these two clinical-stage candidates.
Research is conducted from South San Francisco by a focused team of 43 employees. These programs reflect a focused internal R&D model rather than a multi-segment commercial operation. The company has not realized product revenue from its planned principal operations and contracts manufacturing activities to third-party providers.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Target |
|---|---|---|---|---|---|
| Feb 5, 2026 | Piper Sandler | Reiterate | Overweight | $4 | |
| Mar 6, 2025 | Jefferies | Upgrade | Hold | Buy | |
| Dec 19, 2024 | Jefferies | Downgrade | Buy | Hold |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $138.2M · Total debt $9.7M · Total assets $160.8M · Shareholders' equity $136.2M
- Revenue
- $0
- Operating income
- −$18.0M
- Net income
- −$18.0M
No dividends on record.
| Institutions72 holders · as of Mar 31, 2026 | 68.17% | 94.27M shares | |
| Insiders8 holders · as of Aug 18, 2026 | 10.37% | 14.33M shares | |
| Strategic holders2 holders · as of May 15, 2026 | 10.92% | 15.10M shares | |
| Otherremainder | 10.54% | 14.58M shares |
138.28M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Goodman Corey S.Insider | 9.52% | 13.16M | 13Dfiled Feb 4, 2026 ↗ |
Ra Capital Management, L.P.Institution | 9.41% | 13.01M | 13Fas of Mar 31, 2026 |
TCG Crossover Management, LLCInstitution | 9.41% | 13.01M | 13Fas of Mar 31, 2026 |
Venbio Partners LLCInstitution | 9.32% | 12.88M | 13Fas of Mar 31, 2026 |
HBM Healthcare Investments (Cayman) Ltd.Strategic | 6.21% | 8.59M | 13Gfiled May 15, 2026 ↗ |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 17, 2026 | Shelly Wong | officer: SVP, FINANCE AND CAO | −573 | $1.93 |
| Aug 17, 2026 | Jason Lettmann | director, officer: CHIEF EXECUTIVE OFFICER | −2,230 | $1.93 |
| Jul 1, 2026 | Shelly Wong | officer: SVP, FINANCE AND CAO | −1,404 | $2.04 |
| Mar 19, 2026 | Shelly Pinto | officer: SVP, FINANCE AND CAO | −903 | $2.17 |
| Mar 19, 2026 | Jason Lettmann | director, officer: CHIEF EXECUTIVE OFFICER | −12,311 | $2.17 |
- Bristol-Myers Squibb
EGFR×HER3 ADC development across advanced solid tumors
- AstraZeneca (ADR)
EGFR/c-MET ADC development for solid tumors
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| ALX Oncology | $2.01 | −3.37% | $279.9M | — | — | — | — |
| Bristol-Myers Squibb | $67.65 | −0.01% | $138.21B | 14.9 | 10.6 | 2.8 | +5.7% |
| AstraZeneca (ADR) | $163.48 | +1.13% | $250.67B | 24.3 | 15.2 | 4.1 | +6.4% |
| Median | 19.6 | 12.9 | 3.5 | +6.1% |